A map showing when genes matter during development, not just that they matter
In the long human effort to understand why some minds develop differently from others, a team at Hebrew University of Jerusalem and INSERM has drawn the most detailed map yet of the genome's role in building a brain. By silencing nearly every human gene one at a time, they identified 331 that are indispensable to the earliest moments of neural formation — and in doing so, named a previously unknown disorder affecting children whose brains grew smaller and slower than they should have. The work is less a conclusion than an opening: a shared resource placed before the scientific world as an invitation to keep asking why.
- Nearly 20,000 genes were individually switched off in embryonic stem cells, creating a systematic reckoning with what the brain cannot do without.
- Among the findings, two unrelated children — each carrying mutations in both copies of the PEDS1 gene — were identified as suffering from a disorder that had never before had a name or a cause.
- The disruption runs deeper than one gene: the study revealed that the timing of a genetic fault during development may determine whether a child develops autism, developmental delay, or something else entirely.
- Researchers found that master regulatory genes tend to cause dominant disorders, while metabolic genes like PEDS1 follow a recessive pattern — a relationship that could guide clinicians toward faster, more accurate diagnoses.
- All findings have been released in an open-access database, turning a single laboratory's discovery into a global tool for families and researchers still searching for answers.
A research team at Hebrew University of Jerusalem and INSERM in France has produced what may be the most comprehensive genetic map of early brain development ever assembled. Using CRISPR technology to disable roughly 20,000 genes one at a time in embryonic stem cells, they watched which disruptions prevented normal neural development — and identified 331 genes as absolutely essential to the process. Many had never previously been linked to the brain.
The study did not stop at cataloguing. It also uncovered a previously unknown neurodevelopmental disorder caused by mutations in a gene called PEDS1, which normally helps produce plasmalogens — specialized fats essential to myelin, the insulation around nerve fibers. Two unrelated children, each carrying mutations in both copies of the gene, were found to have developmental delay and noticeably reduced brain size. When PEDS1 was inactivated in laboratory models, the same pattern emerged: nerve cells failed to form and migrate correctly.
The discovery illuminated a broader principle. Genes that act as master regulators tend to cause dominant disorders — one faulty copy is enough. Metabolic genes like PEDS1 typically require both copies to be disrupted before disease appears. Understanding this relationship could help clinicians know where to look when a child presents with developmental difficulties.
The team also found that the timing of a genetic disruption during development may shape which condition emerges — genes broadly essential throughout development correlated more with developmental delay, while those critical specifically during neuron formation correlated more with autism. This temporal dimension could reframe how researchers understand the overlap between these conditions.
All data has been made publicly available through the Neuronal Differentiation Essential Genes Dataset, built largely by Ph.D. student Alana Amelan. For affected families, the work offers a path toward diagnosis and counseling. For the field, it offers a foundation.
A team of researchers at Hebrew University of Jerusalem and INSERM in France has completed what amounts to a genetic instruction manual for building a brain. By systematically disabling nearly every gene in the human genome one at a time, they identified 331 genes that are absolutely required for embryonic stem cells to transform into functioning brain cells. The work, published in Nature Neuroscience, represents the most comprehensive map yet of which genetic switches must stay on for early brain development to proceed normally.
The method was elegant in its directness. The researchers used CRISPR gene-editing technology to knock out roughly 20,000 genes individually while watching embryonic stem cells differentiate into neurons. Each time they switched off a gene, they could observe whether the cells still developed properly or whether something essential had been lost. Over time, a pattern emerged: 331 genes proved absolutely critical to the process. Many of these had never before been connected to brain development, suggesting that our understanding of how the brain forms has been incomplete.
But the study did more than add to a catalog of important genes. It also identified a previously unknown genetic disorder. The researchers discovered that mutations in a gene called PEDS1 cause severe developmental problems in children. PEDS1 normally helps produce plasmalogens, specialized fats that make up myelin—the insulation around nerve fibers. When the gene doesn't work properly, brain development falters. The team found two unrelated families, each with a child carrying mutations in both copies of the PEDS1 gene. Both children showed developmental delay and noticeably smaller brains. When the researchers inactivated PEDS1 in laboratory models, the same problems appeared: nerve cells failed to form and migrate correctly, and overall brain size diminished.
The discovery of PEDS1 as a disease-causing gene illustrates how this kind of systematic screening can move directly from the lab to the clinic. Prof. Sagiv Shifman, who led the research, explained that the team had created a map showing not just which genes matter, but when they matter during development. This temporal dimension proved revealing. Genes that regulate other genes—the master switches of the genome—tend to cause dominant disorders, where a mutation in just one copy is enough to cause disease. Metabolic genes like PEDS1, by contrast, typically cause recessive disorders, requiring mutations in both copies. This relationship between a gene's function and its inheritance pattern could help clinicians recognize which genes to investigate when a child presents with developmental problems.
The researchers also uncovered something unexpected about the relationship between different neurodevelopmental conditions. Genes that are broadly essential throughout development correlated more strongly with developmental delay, while genes critical specifically during nerve cell formation correlated more strongly with autism. This suggests that the timing of when a genetic disruption occurs during brain development may help determine which condition emerges—a finding that could reshape how researchers think about the overlap between these disorders.
To ensure the work benefits the broader scientific community, the team has made all their data publicly available through an online database called the Neuronal Differentiation Essential Genes Dataset. The database was built by Alana Amelan, a Ph.D. student who carried out much of the experimental work. Shifman noted that the goal was to create a resource that would accelerate discovery, allowing researchers worldwide to investigate the genes the team identified and to search for additional genes involved in neurodevelopmental disorders. For families with children affected by conditions like the PEDS1-related disorder, the work opens a path toward better genetic diagnosis and counseling. For the field more broadly, it provides a foundation for understanding how disruptions in early brain development lead to lasting neurological differences.
Citações Notáveis
By tracking the differentiation of embryonic stem cells into neural cells and systematically disrupting nearly all genes in the genome, we created a map of the genes essential for brain development.— Prof. Sagiv Shifman, Hebrew University of Jerusalem
Identifying PEDS1 as a genetic cause of developmental impairment in children opens the door to improved diagnosis and genetic counseling for families, and may eventually support the development of targeted treatments.— Prof. Sagiv Shifman
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that you can identify when a gene is essential during development, rather than just knowing it's essential at all?
Because timing tells you something about what the gene does. A gene that's critical throughout development is probably doing something fundamental that the whole brain needs. A gene that's only critical during the stage when neurons are forming might be doing something more specific. That difference helps explain why some genetic mutations cause broad developmental delay while others lead to autism specifically.
So when you found PEDS1, you didn't just discover a new gene—you discovered a new disease?
Exactly. We found that PEDS1 was essential in our screen, then we looked at the human genetics literature and found two families with children who had mutations in this gene. The children had the exact problems we'd predicted from the lab work—small brains, developmental delay. That's the power of this approach. The screen generates hypotheses that you can then test against real human cases.
The fact that PEDS1 is recessive—that both copies need to be mutated—does that make it harder to find?
In some ways, yes. Recessive disorders are rarer because both parents have to carry the mutation. But once you know what to look for, it becomes easier to diagnose. And for families, knowing the inheritance pattern changes everything. It means genetic counseling can be more precise. It means parents understand the risk differently.
You're releasing all this data publicly. Why not keep it proprietary?
Because the point isn't to own the discovery—it's to understand the brain. If researchers around the world can access this map, they'll find things we missed. They'll connect these genes to conditions we haven't thought of yet. One person's dataset becomes a thousand people's research tool.
What happens to the children with PEDS1 mutations now?
That's the honest answer: we don't have a treatment yet. But we have a diagnosis. We understand what's happening in their cells. That's the foundation. Diagnosis opens the door to genetic counseling, to family planning, and eventually to research into whether we can intervene. It's not a cure, but it's not nothing either.